Decision: Favourable
Study Title:
An open-label, randomized, Phase 3 clinical trial of IO102- IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic (advanced) melanoma
NREC Code:
22-NREC-CT-086
Decision:
Favourable
Study Type:
CT application
Principal Investigator:
Prof. Paul Donnellan
PI Institution:
University Hospital Galway
Sponsor:
IO Biotech ApS